Literature DB >> 29328515

Magnetic resonance imaging in facioscapulohumeral muscular dystrophy.

Doris G Leung1,2.   

Abstract

Entities:  

Mesh：

Year:  2018        PMID： 29328515      PMCID： PMC5951734          DOI： 10.1002/mus.26064

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN： 0148-639X            Impact factor:   3.217


× No keyword cloud information.
  22 in total

1.  A prospective, quantitative study of the natural history of facioscapulohumeral muscular dystrophy (FSHD): implications for therapeutic trials. The FSH-DY Group.

Authors: 
Journal:  Neurology       Date:  1997-01       Impact factor: 9.910

2.  DICER/AGO-dependent epigenetic silencing of D4Z4 repeats enhanced by exogenous siRNA suggests mechanisms and therapies for FSHD.

Authors:  Jong-Won Lim; Lauren Snider; Zizhen Yao; Rabi Tawil; Silvère M Van Der Maarel; Frank Rigo; C Frank Bennett; Galina N Filippova; Stephen J Tapscott
Journal:  Hum Mol Genet       Date:  2015-06-03       Impact factor: 6.150

3.  A randomized placebo-controlled phase 3 trial of an antisense oligonucleotide, drisapersen, in Duchenne muscular dystrophy.

Authors:  Nathalie Goemans; Eugenio Mercuri; Elena Belousova; Hirofumi Komaki; Alberto Dubrovsky; Craig M McDonald; John E Kraus; Afrodite Lourbakos; Zhengning Lin; Giles Campion; Susanne X Wang; Craig Campbell
Journal:  Neuromuscul Disord       Date:  2017-12-06       Impact factor: 4.296

4.  MRI as outcome measure in facioscapulohumeral muscular dystrophy: 1-year follow-up of 45 patients.

Authors:  Grete Andersen; Julia R Dahlqvist; Christoffer R Vissing; Karen Heje; Carsten Thomsen; John Vissing
Journal:  J Neurol       Date:  2016-12-20       Impact factor: 4.849

5.  MRI change metrics of facioscapulohumeral muscular dystrophy: Stir and T1.

Authors:  Mark R Ferguson; Sandra L Poliachik; Christopher B Budech; Nancy E Gove; Gregory T Carter; Leo H Wang; Daniel G Miller; Dennis W W Shaw; Seth D Friedman
Journal:  Muscle Nerve       Date:  2018-03-03       Impact factor: 3.217

Review 6.  A Systematic Review and Meta-analysis on the Epidemiology of the Muscular Dystrophies.

Authors:  Jean K Mah; Lawrence Korngut; Kirsten M Fiest; Jonathan Dykeman; Lundy J Day; Tamara Pringsheim; Nathalie Jette
Journal:  Can J Neurol Sci       Date:  2016-01       Impact factor: 2.104

7.  CRISPR/dCas9-mediated Transcriptional Inhibition Ameliorates the Epigenetic Dysregulation at D4Z4 and Represses DUX4-fl in FSH Muscular Dystrophy.

Authors:  Charis L Himeda; Takako I Jones; Peter L Jones
Journal:  Mol Ther       Date:  2015-11-03       Impact factor: 11.454

8.  Whole-body magnetic resonance imaging evaluation of facioscapulohumeral muscular dystrophy.

Authors:  Doris G Leung; John A Carrino; Kathryn R Wagner; Michael A Jacobs
Journal:  Muscle Nerve       Date:  2015-03-31       Impact factor: 3.852

9.  Individual epigenetic status of the pathogenic D4Z4 macrosatellite correlates with disease in facioscapulohumeral muscular dystrophy.

Authors:  Takako I Jones; Oliver D King; Charis L Himeda; Sachiko Homma; Jennifer C J Chen; Mary Lou Beermann; Chi Yan; Charles P Emerson; Jeffrey B Miller; Kathryn R Wagner; Peter L Jones
Journal:  Clin Epigenetics       Date:  2015-03-29       Impact factor: 6.551

10.  Distinct disease phases in muscles of facioscapulohumeral dystrophy patients identified by MR detected fat infiltration.

Authors:  Barbara H Janssen; Nicoline B M Voet; Christine I Nabuurs; Hermien E Kan; Jacky W J de Rooy; Alexander C Geurts; George W Padberg; Baziel G M van Engelen; Arend Heerschap
Journal:  PLoS One       Date:  2014-01-14       Impact factor: 3.240
View more
  1 in total

1.  Tracking muscle wasting and disease activity in facioscapulohumeral muscular dystrophy by qualitative longitudinal imaging.

Authors:  Mauro Monforte; Francesco Laschena; Pierfrancesco Ottaviani; Maria Rosaria Bagnato; Anna Pichiecchio; Giorgio Tasca; Enzo Ricci
Journal:  J Cachexia Sarcopenia Muscle       Date:  2019-10-30       Impact factor: 12.910
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.